Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1321 to 1330 of 2733 total matches.
Monthly Risedronate (Actonel) for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Sep 08, 2008 (Issue 1294)
available in a tablet given once monthly.
1
Oral bisphosphonates can cause heartburn, esophageal ...
The bisphosphonate risedronate (Actonel - Procter & Gamble) was recently approved by the FDA in a 150- mg once-monthly oral tablet for prevention and treatment of postmenopausal osteoporosis. The drug is also available for the same indication in 5-mg daily, 35-mg weekly and 75-mg twice-monthly tablets.
Insulin Glargine (Lantus) and Cancer Risk
The Medical Letter on Drugs and Therapeutics • Aug 24, 2009 (Issue 1319)
insulin.
1
DIABETES AND CANCER — Type 2 diabetes has
been associated with an increased risk of breast ...
Several large European observational studies published on-line this summer have raised questions about whether use of insulin glargine increases the risk of cancer.
A Third Amlodipine/ARB Combination (Twynsta) for Hypertension
The Medical Letter on Drugs and Therapeutics • Jan 11, 2010 (Issue 1329)
of
hypertension.
1
CALCIUM-CHANNEL BLOCKERS — CCBs cause
vasodilation, which decreases peripheral resistance ...
The FDA has approved Twynsta (Boehringer Ingelheim), a fixed-dose combination of the calcium-channel blocker (CCB) amlodipine and the angiotensin receptor blocker (ARB) telmisartan, for treatment of hypertension.
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
The Medical Letter on Drugs and Therapeutics • Jan 24, 2011 (Issue 1356)
-lactams, it has a high affinity in vitro for
PBP2a, a unique PBP encoded by the mecA gene in
MRSA.1 ...
The FDA has approved ceftaroline fosamil (Teflaro –
Forest), an intravenous (IV) cephalosporin, for treatment
of acute bacterial skin and skin structure infections,
including those caused by methicillin-resistant
Staphylococcus aureus (MRSA), and for treatment of
community-acquired bacterial pneumonia in adults. It
is the first beta-lactam antibiotic approved for treatment
of MRSA.
New Simvastatin Dosing Recommendations
The Medical Letter on Drugs and Therapeutics • Aug 08, 2011 (Issue 1370)
with other drugs.1 Simvastatin
is available alone (Zocor, and others) and in combination
with ezetimibe (Vytorin ...
The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or more without evidence of myopathy and new recommendations for use of simvastatin with other drugs. Simvastatin is available alone (Zocor, and others) and in combination with ezetimibe (Vytorin) and with niacin (Simcor).
Maestro Rechargeable System for Weight Loss
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016 (Issue 1493)
procedures such as adjustable gastric
banding or sleeve gastrectomy.1 Gastric balloon devices
are inserted ...
The FDA has approved the Maestro Rechargeable
System (EnteroMedics), a subcutaneously implanted
device, for use in adults who have not been able to lose
weight with a weight loss program within the past 5 years
and who have a body mass index (BMI) of 40 to 45, or a
BMI ≥35 and at least one obesity-related comorbidity.
Etrasimod (Velsipity) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
Etrasimod (Velsipity) for Ulcerative Colitis
The oral sphingosine 1-phosphate (S1P) receptor ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator etrasimod (Velsipity – Pfizer) has been
approved by the FDA for treatment of moderately to
severely active ulcerative colitis in adults. It is the
second oral S1P receptor modulator to be approved
in the US for this indication; ozanimod (Zeposia) was
the first.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):187-9 doi:10.58347/tml.2023.1690b | Show Introduction Hide Introduction
IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
with reduced quality of life and increased
hospitalization and mortality.1 Injectafer is the first
IV iron ...
Ferric carboxymaltose (Injectafer – American
Regent) is now FDA-approved for IV treatment of iron
deficiency in adults with New York Heart Association
(NYHA) class II/III heart failure to improve exercise
capacity. Iron deficiency is present in approximately
30% of patients with heart failure; it has been
associated with reduced quality of life and increased
hospitalization and mortality. Injectafer is the first
IV iron preparation to be approved for this indication.
It was previously approved for treatment of iron
deficiency anemia in children and adults.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):22-4 doi:10.58347/tml.2024.1695d | Show Introduction Hide Introduction
Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder (online only)
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
and a female to male
ratio of 4:1. It is characterized by early onset (within
3 months of birth), multiple ...
The FDA has approved ganaxolone (Ztalmy – Marinus)
for oral treatment of seizures associated with cyclin-dependent
kinase-like 5 (CDKL5) deficiency disorder
in patients ≥2 years old. It is the first drug to be
approved in the US for this indication.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):e139-40 doi:10.58347/tml.2024.1709g | Show Introduction Hide Introduction
Iptacopan (Fabhalta) for Paroxysmal Nocturnal Hemoglobinuria (online only)
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024 (Issue 1712)
(estimated
prevalence 38 cases per 1,000,000 persons) caused
by a severe deficiency in the complement ...
The FDA has approved the complement factor B
inhibitor iptacopan (Fabhalta – Novartis) for
treatment of paroxysmal nocturnal hemoglobinuria
(PNH) in adults. Iptacopan is the first oral drug to
be approved in the US for this indication. Three
parenterally administered drugs, the complement
C5 inhibitors eculizumab (Soliris) and ravulizumab
(Ultomiris) and the complement C3 inhibitor
pegcetacoplan (Empaveli), are also approved for
treatment of PNH.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e171-3 doi:10.58347/tml.2024.1712e | Show Introduction Hide Introduction
